Macro Group registers 59% YoY drop in H1 consolidated profits
Updated 8/16/2023 9:22:00 AM
Arab Finance: Macro Group Pharmaceutical (Macro Capital) reported a 58.88% year-on-year (YoY) decline in consolidated profits attributable to the parent company during the first half (H1) of 2023, according to the financial statement filed to the Egyptian Exchange (EGX) on August 16th.
The group recorded a consolidated net profit excluding minority interest of EGP 29.337 million in H1 2023, compared to EGP 71.349 million in H1 2022.
Consolidated sales soared to EGP 337.235 million in H1 2023 from EGP 305.134 million in H1 2022.
The firm achieved standalone net profits after tax of EGP 30.336 million during the January-June period of this year, down from EGP 72.337 million in the first six months of 2022.
Founded in 2002, Macro Group is a leading Egyptian cosmeceutical company based in Cairo.
Related News
